- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Pharmaceutical
Canada’s Supreme Court won’t hear Lilly appeal on Zyprexa
May 16, 2013
Bloomberg NewsEli Lilly claims recent decisions by Canadian courts invalidating 17 drug patents have made the country an outlier among major
developed countries.
MoreLilly stops development on cancer drug after failed study
May 10, 2013
Bloomberg NewsThe drug, enzastaurin, was in the most advanced stage of testing and had been expected to generate $260 million in annual
sales by 2018.
MoreLilly's sales-force restructuring to affect 1,600-plus
May 6, 2013
J.K. WallLilly will eliminate 1,624 positions from its U.S. sales force in July, according to a notice the company made to state officials.
But some of those workers may be rehired by the firm.
MoreLilly taking hard look at Pfizer's new Viagra strategy
May 6, 2013
Associated PressMajor drugmakers, including Indianapolis-based Eli Lilly and Co., are closely watching Pfizer Inc.'s plan to sell Viagra directly
to consumers. The bold move blows up the drug industry's distribution model.
MoreLilly suing J&J for patent rights in Alzheimer's drug race
April 25, 2013
Bloomberg NewsEli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay
availability of a potential treatment for Alzheimer’s disease.
MoreNora pharmacy recalls compounded drugs
April 23, 2013
Associated PressA pharmacy that makes specialty medications is recalling nearly 100 compounded drugs after federal regulators found potential
safety problems during an inspection.
MoreLilly on the rise as investors run back to pharma stocks
April 22, 2013
J.K. WallInvestors are gaining confidence in the ability of major drugmakers, including Eli Lilly and Co., to improve their pipelines
of new products. The big pharma firms begin to report first-quarter earnings this week.
MoreLilly's $30.6M tax abatement request clears hurdle
April 18, 2013
IBJ StaffThe pharmaceutical firm has $400 million in projects in the works for its facilities south of downtown. City officials have
advanced its request for tax breaks to a public hearing and final consideration May 1.
MoreLilly seeks $30.6M in tax breaks on downtown projects
April 15, 2013
Mason KingIndianapolis development officials on Wednesday will weigh the 10-year requests from the pharmaceuticals giant related to
a new manufacturing plant and improvements to existing operations downtown.
MoreExpected revenue slump spurs Lilly to cut sales force
April 11, 2013
J.K. WallThe Indianapolis pharmaceuticals giant said Thursday that it would lay off hundreds of U.S. sales reps, as it prepares for
the loss of patent protection on two of its best-selling drugs.
MoreJ&J wins OK for first in new class of diabetes drugs
March 31, 2013
Bloomberg NewsJohnson & Johnson, the world’s largest seller of health-care products, won approval for the first in a new family
of diabetes drugs, giving them the edge against rivals including Eli Lilly and Co. that are developing similar medicines.
MoreLilly, Boehringer submit diabetes drug to FDA
March 25, 2013
Associated PressEli Lilly and Co. said Monday that it has submitted a new type 2 diabetes treatment it is developing with German drugmaker
Boehringer Ingelheim to the Food and Drug Administration.
MoreIndiana lawmakers advance tighter cold meds limits
March 25, 2013
Associated PressConsumers would face tighter limits on the quantities they could buy of cold and allergy pills often used to make methamphetamine
under a proposal approved by Indiana lawmakers.
MoreCourt may decide if drugmakers can pay to delay generics
March 25, 2013
Associated PressFederal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors
to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for
years, steep price declines.
MoreDrugmakers, Interpol ramp up fight against fakes
March 12, 2013
Associated PressMore than two dozen of the world's largest pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., have
agreed to provide funding and other support to Interpol's battle against counterfeit prescription drugs.
MoreLilly sues Genentech to invalidate Erbitux-related patents
March 2, 2013
Bloomberg NewsEli Lilly and Co. has sued Roche Holding AG’s Genentech unit, asking a court to invalidate patents used to make treatments
for cancer and autoimmune diseases.
MoreEndocyte stock sinks due to possible drug-filing delay
February 26, 2013
J.K. WallEndocyte Inc. saw its shares fall nearly 7 percent Tuesday morning after the drug development firm announced that its application
for U.S. approval of a cancer drug could be delayed another 10 months.
MoreLilly to expand partnership with diagnostic firm
February 14, 2013
IBJ Staff and Associated PressDiagnostic products maker Qiagen NV said Wednesday that it will work with Eli Lilly and Co. to develop new tests that could
identify patients who could be helped by Lilly's drugs.
MoreLilly halts late-stage testing of rheumatoid arthritis drug
February 7, 2013
Bloomberg NewsEli Lilly said it is halting testing of experimental drug tabalumab because the studies show the medicine is not effective.
The company said it expects to take a $50 million charge in the first quarter related to the research expenses from the drug.
MoreStruggling Greenwood biotech firm finds buyer
February 7, 2013
IBJ StaffElona Biotechnologies Inc., which has been struggling to repay Greenwood for more than $8 million in economic development
incentives, says it has solution to its financial problems.
MoreLilly aims to submit five new drugs for approval
February 4, 2013
J.K. WallWith Eli Lilly and Co. set to see patents expire on its best-selling drug at year’s end, it is in the company’s
interest to say its pipeline is about to produce new drugs. But the Indianapolis drugmaker may be in a position to submit
five new drugs for regulatory approval this year.
MoreLaw firm adds pharmacy practice
February 2, 2013
Hall Render Killian Heath & Lyman will draw on existing expertise within the firm to create the 10-member group.
MoreOnce-thriving drug lab in turnaround mode
January 26, 2013
J.K. WallTwo years ago, executives at AIT Laboratories “took their eye off the ball,” and watched the company’s business
plummet 29 percent in value. Now, after two years of turmoil, the drug-testing lab says it’s poised to return to the
double-digit rates of growth that made it a local star.
MoreGreenwood seeks funds back from drugmaker with big plans
January 22, 2013
J.K. WallGreenwood-based Elona Biotechnologies Inc., which has been trying to bring a generic version of insulin to market, was declared
in default on $8.4 million in incentives from the city of Greenwood.
MoreLilly's Amyvid receives European approval
January 16, 2013
Associated PressEuropean regulators approved the use of an imaging agent from Eli Lilly and Co., which can help doctors diagnose Alzheimer's
disease.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Three Magi
Cats out of the bag. The object of the game is to get acquired. That means the company has no idea how to grow beyond a certain point. Email is a 1990s technology. I have laughed at this company since day one. Such a small bit player. If it was anywhere but here, it wouldn't be newsworthy.
Esther, Indy has passed Chicago in the local government corruption arena. Don't downgrade us. We're No. 1 in the Midwest.
Does the buyer get to keep the recent Accu-Chek J.D. Power award? Be careful, those Swiss cannot be trusted. Last June they pimped Mayor Ballard and former Governor Daniels at a media op, announcing plans to invest "$300 million at its Indianapolis headquarters, creating up to 100 new jobs by 2017," only to turn around and close the Roche Nutley, NJ facility and eliminate 1000 jobs there later the same week. It seems that healthcare can be innovated only as long as money is to be made. Right now Roche seems to have big eyes for China: there are many Chinese in China and potential billions in Swiss francs! Since Roche is having difficulty with US insurance companies swallowing the bill for overpriced cancer drugs (with debatable efficacy) why not sell insurance to the Chinese and market the drugs to them there? There is a name for these sort of business practices however proper decorum precludes it use in this forum.
Same kind of Luddites who oppose I-69. Guessing their 501(c)(4) application probably sailed right through the IRS.